Nyxoah Q4 Revenue Jumps 347% as US Commercialization Exceeds Expectations
NYXH is trading near its 52-week low of $3.05 (3.9% above the low) on light trading volume (0.4× avg).
Summary
Nyxoah reported robust fourth quarter and full year 2025 financial results, with Q4 net revenue soaring 347% year-over-year to €5.6 million, driven by the first full quarter of U.S. commercialization for its Genio system. Full year net revenue also grew significantly by 122% to €10.0 million. The company exceeded its revenue expectations, successfully trained 145 surgeons, activated 57 U.S. accounts, and secured consistent reimbursement from major commercial payors and Medicare. While the company reported widening net losses for both the quarter and full year, the strong top-line growth and successful market penetration in the U.S. are critical indicators of progress for this growth-stage medical technology firm. Traders will be watching for continued momentum in U.S. adoption and further progress towards profitability.
At the time of this announcement, NYXH was trading at $3.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.9M. The 52-week trading range was $3.05 to $11.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.